Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer

P. Venook, Alan; Niedzwiecki, Donna; Lenz, Heinz‐Josef; Innocenti, Federico; Fruth, Briant; A. Meyerhardt, Jeffrey; Schrag, Deborah; Greene, Claire; H. O’Neil, Bert; N. Atkins, James; Berry, Scott; N. Polite, Blasé; M. O’Reilly, Eileen; M. Goldberg, Richard; S. Höchster, Howard; L. Schilsky, Richard; M. Bertagnolli, Monica; B. El-Khoueiry, Anthony; J. Watson, Peter; B. Benson, Al; Mulkerin, Daniel; J. Mayer, Robert; D. Blanke, Charles

doi:10.1001/jama.2017.7105

Public

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer

Published in JAMA • Jun 20, 2017

Authors:

Alan P. Venook

Donna Niedzwiecki

Heinz‐Josef Lenz

Abstract

Importance: Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic colorectal cancer, but the optimal choice of the initial biologic therapy in previously untreated patients is unknown. Objective: To determine ...

Subject

Medicine

Bevacizumab

Cetuximab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!